HK1256099A1 - 用於治療移植物抗宿主病的組合物和方法 - Google Patents

用於治療移植物抗宿主病的組合物和方法

Info

Publication number
HK1256099A1
HK1256099A1 HK18115164.8A HK18115164A HK1256099A1 HK 1256099 A1 HK1256099 A1 HK 1256099A1 HK 18115164 A HK18115164 A HK 18115164A HK 1256099 A1 HK1256099 A1 HK 1256099A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
host disease
versus host
graft versus
Prior art date
Application number
HK18115164.8A
Other languages
English (en)
Inventor
劉陽
王茵
Original Assignee
兒研所兒童醫學中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 兒研所兒童醫學中心 filed Critical 兒研所兒童醫學中心
Publication of HK1256099A1 publication Critical patent/HK1256099A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18115164.8A 2015-08-19 2018-11-27 用於治療移植物抗宿主病的組合物和方法 HK1256099A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562207000P 2015-08-19 2015-08-19
PCT/US2016/047595 WO2017031341A1 (en) 2015-08-19 2016-08-18 Compositions and methods for treating graft versus host disease

Publications (1)

Publication Number Publication Date
HK1256099A1 true HK1256099A1 (zh) 2019-09-13

Family

ID=58052028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115164.8A HK1256099A1 (zh) 2015-08-19 2018-11-27 用於治療移植物抗宿主病的組合物和方法

Country Status (6)

Country Link
US (1) US10898522B2 (zh)
EP (1) EP3337491A4 (zh)
CN (1) CN108135941B (zh)
CA (1) CA2995582A1 (zh)
HK (1) HK1256099A1 (zh)
WO (1) WO2017031341A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte
CN114732807A (zh) * 2022-03-27 2022-07-12 苏州大学 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296366A1 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
KR20120038546A (ko) * 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
WO2004071443A2 (en) * 2003-02-12 2004-08-26 Irm Llc Methods and compositions for modulating stem cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7629128B2 (en) * 2004-08-30 2009-12-08 Prolx Pharmaceuticals Corp. Methods of identifying respondents to hypoxia inducible factor 1-α inhibitors
US20080213404A1 (en) * 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
US7312217B2 (en) * 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
CN101269088A (zh) * 2007-03-23 2008-09-24 中山大学 用于预防与治疗慢性移植物抗宿主病的干细胞制剂
CN101687019A (zh) * 2007-04-24 2010-03-31 迪亚米德治疗股份公司 用于治疗自身免疫性疾病和癌症的药物和方法
WO2009001545A1 (ja) * 2007-06-22 2008-12-31 Sapporo Medical University 移植片対宿主疾患の検査および治療方法
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
NZ590330A (en) * 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
CA2720567C (en) * 2009-11-09 2016-06-21 The Jackson Laboratory Transgenic non-human animal and methods for stem cell engraftment
LT2506840T (lt) * 2009-12-04 2021-06-25 OncoC4, Inc. Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
US8586363B2 (en) 2009-12-10 2013-11-19 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
WO2011146607A2 (en) 2010-05-18 2011-11-24 President And Fellows Of Harvard College Stable reprogrammed cells
EP2658965B1 (en) 2010-12-31 2016-03-02 Universität für Bodenkultur Wien Method of generating induced pluripotent stem cells and differentiated cells
WO2012116111A1 (en) 2011-02-22 2012-08-30 Sanford-Burnham Medical Research Institute METHOD AND COMPOUNDS FOR GENERATION OF iPSCs
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
US20130236453A1 (en) * 2012-03-12 2013-09-12 The Ohio State University Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors
JP5883539B2 (ja) * 2012-03-16 2016-03-15 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｈｉｆ−１阻害剤の送達のための放出制御製剤
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
CN104919048B (zh) 2012-10-01 2018-10-26 台北荣民总医院 制备诱导多能干细胞的方法及其应用
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN103146646A (zh) * 2013-02-22 2013-06-12 浙江大学 一种动员间充质干细胞的制剂及分离方法
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
AU2014359077A1 (en) * 2013-12-06 2016-07-21 Novimmune S.A. Anti-TLR4 antibodies and methods of use thereof
WO2017083403A1 (en) * 2015-11-10 2017-05-18 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof

Also Published As

Publication number Publication date
EP3337491A1 (en) 2018-06-27
EP3337491A4 (en) 2019-04-10
WO2017031341A1 (en) 2017-02-23
CN108135941A (zh) 2018-06-08
CA2995582A1 (en) 2017-02-23
US10898522B2 (en) 2021-01-26
CN108135941B (zh) 2021-07-27
US20180236002A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
IL267247B (en) Compositions and methods for treating cancer
HK1232141A1 (zh) 用於治療亨廷頓病的方法和組合物
IL304820A (en) Preparations and methods for the treatment of cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
PT3377516T (pt) Composição para o tratamento do cancro
IL263460A (en) Preparations and methods for the treatment of cardiovascular diseases
HK1254432A1 (zh) 用於治療纖維性疾病的方法和組合物
HK1251482A1 (zh) 用於治療補體介導的疾病的組合物和方法
RS61929B1 (sr) Postupci i sastavi za tretman raka
IL256523A (en) Compositions and methods for treating cancer
PT3261644T (pt) Composições e métodos para tratar a degradação retinal
IL288768A (en) Compounds and methods for the treatment of celiac disease
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3322406A4 (en) TRANSPARENT METHODS AND COMPOSITIONS FOR THE TREATMENT OF MAMMARY DISEASES
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
IL255638A (en) Compositions and methods for treating cancer
HK1256099A1 (zh) 用於治療移植物抗宿主病的組合物和方法
IL261767A (en) Methods for treating or preventing graft-versus-host disease
IL261750A (en) A method for preventing graft-versus-host disease
ZA201802268B (en) Methods and compositions for preventing or treating cancer
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
EP3310338A4 (en) Compositions and methods for treating inflammatory disease or conditions
HK1250958A1 (zh) 用於治療癌症的組合物和方法
EP3496696A4 (en) COMPOUNDS AND METHODS FOR TREATING THE DISEASE.